Please try another search
For the three months ended 31 March 2022, Acerus Pharmaceuticals Corporation revenues increased from $234K to $782K. Net loss decreased 46% to $7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Termination Fees decrease from $6.2M (expense) to $0K, Selling and marketing decrease of 13% to $4.6M (expense).
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Revenue | 0.78 | 0.74 | 0.59 | 0.56 |
Gross Profit | 0.53 | 0.34 | 0.1 | 0.52 |
Operating Income | -5.36 | -8.2 | -3.97 | -6.75 |
Net Income | -6.95 | -9.02 | -4.9 | -7.07 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Assets | 47.77 | 9.65 | 11.35 | 10.36 |
Total Liabilities | 52.38 | 35.67 | 29.95 | 25.3 |
Total Equity | -4.61 | -26.01 | -18.61 | -14.94 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -4.66 | -23.52 | -16.26 | -11.75 |
Cash From Investing Activities | -0.69 | -0.02 | 0.04 | 0.04 |
Cash From Financing Activities | 6.76 | 16.54 | 9.34 | 5.16 |
Net Change in Cash | 1.4 | -6.99 | -6.88 | -6.55 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review